Retour à l'accueil - Logo CERMN

EA 4258 | Centre d'études et de recherche sur le médicament de Normandie

Home > Research programmes > Polypharmacology > PLEIAD


PLEIAD · Pleiotropic Agents for Alzheimer’s Disease · programme is designed to develop pleiotropic agents of potentially therapeutic interest in the treatment of Alzheimer’s Disease (AD).  It consists in studying the relevance and the possibility of giving a single molecule, activities that are selectively oriented towards several targets of interest in AD. This translational and multithematic research programme is developed in association with the Institut de Génomique Fonctionnelle (IGF) at Montpellier and the Groupe Mémoire et Plasticité comportementale (GMPc) in Caen. PLEIAD has received funding notably from the Emergence regional fund for innovation, the ANR fund JCJC MALAD ·  Christophe Rochais, from the LECMA (Ligue Européenne Contre la Maladie d'Alzheimer) and from the Fondation Plan Alzheimer.
The targets, which could be the objects of a possible association in this field, are the 5-HT4 and 5-HT6  serotonergic receptors, the H3 histaminergic receptor, the catalytic and peripheral sites of the acetylcholinesterase · AchE · and the aggregation of beta-amyloid peptides and the TAU protein. The research programme has notably led to the recent discovery of Donécopride, an agonist of the 5-HT4 receptor and an inhibitor of Acetylcholinesterase, which has been the object of a significant development programme and the laureate of PreclinicAlz funding.

Download page

Last update : July 4, 2016


Pr Christophe Rochais
+33 (0)2 31 56 68 13

Université de Caen Normandie
CERMN Centre détudes et de recherche sur le médicament de Normandie
Boulevard Becquerel | 14032 Caen Cedex | France